Vagus Nerve Stimulators Market, By Product Type (Implantable Devices and External Devices), By Application (Epilepsy, Depression & Anxiety, Migraine, and Others), By Material Type (Ceramics, Metallics, and Polymerics) , By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Mar 2024

Code : CMI2514

Pages :162

Formats :

Excel and PDF

Industry : Medical Devices

Key Developments

On February 21, 2024, Tivic Health Systems, Inc., a health technology firm, announced that the enrollment in a pilot clinical study of a novel approach to non-invasive vagus nerve stimulation (VNS) is now complete. Implanted VNS is being utilized to treat a variety of neurologic and psychiatric disorders, and it is also being investigated in systemic inflammatory diseases. Tivic Health Systems, Inc. is developing a patented approach to more accurately regulate vagus nerve signals while improving effectiveness and safety through non-invasive treatment.
On January 4, 2024, Pulsetto, a medical device company, announced that it will showcase its pioneering vagus nerve stimulation device at the Consumer Electronics Show, which took place in Las Vegas, U.S., from January 9 to 12, 2024. More than just a stress-relief tool, Pulsetto has a proven track record in helping improve sleep quality and facilitating overall body recovery. Its electric stimulation technique activates the vagus nerve in 4 minutes, making it one of the quickest ways to relax and unwind.
In April 2023, MicroTransponder, Inc., a medical device firm, announced that the Vivistim Paired VNS System has earned the 2023 Gold Edison Award for being a game-changing product that enables stroke survivors to live more fulfilling lives. The Edison Awards recognize innovations that improve people's safety, health, and productivity.
In August 2021, MicroTransponder, Inc. announced that the Vivistim Paired VNS System has received premarket approval from the U.S. Food and Drug Administration (FDA), which significantly improves the effectiveness of rehabilitation therapy for stroke survivors with moderate to severe upper extremity impairment six months after the stroke.